Bioventus Inc. Q3 FY2026 earnings call

• Strategic Review: BioVentus is evaluating strategic options following an unsolicited acquisition proposal. The process is ongoing with no updates provided or questions answered on this topic.
• Growth Drivers Investment: Accelerating long-term revenue growth through increased investment in four key areas: PNS, PRP, Ultrasonics, and International business. Total incremental investment accelerated from $13 million to nearly $15 million for the year.
• Platelet-Rich Plasma (PRP): Momentum building with sequential growth in capital placements. Disposable kit revenue now exceeds capital placement revenue. Secured exclusive rights from Apex Biologics for sports medicine accounts.
• Peripheral Nerve Stimulation (P&S): Gaining traction with encouraging physician feedback. Trial-to-permanent conversion rates exceed plans. Physician training grew >50% quarter-over-quarter. Expects to scale to over $100 million in coming years.
• Ultrasonics: Delivered strong double-digit revenue growth. Surgeon adoption and disposables volume accelerating. Expected to pave the way for further growth acceleration in 2027.
• International Business: Revenue accelerated 16% in Q3. Talent additions and focused market strategy driving success. Expect strong double-digit growth in Q4 and full year.
• Financial Discipline: Despite higher investments, adjusted EBITDA margin expanded 70 basis points to 20%. Adjusted EPS rose 13% to 17 cents. Cash flow from operations was $21 million, funding $19 million in term loan repayments.
• Debt Reduction: Net debt lowered to below $200 million. Year-to-date term loan repayments totaled $65 million. Net leverage ratio expected to be below 1.5x by year-end.

• Global Pain Treatments: Revenue of $71 million, up 6% year-over-year (YoY). Contributed approximately 50% of total revenue. Growth driven by Hyaluronic Acid (HA) portfolio strength and early traction in Platelet-Rich Plasma (PRP) and Peripheral Nerve Stimulation (PNS).
• Surgical Solutions: Revenue of $51 million, up 1% YoY. Contributed approximately 36% of total revenue. Ultrasonics delivered strong double-digit growth. Bone Graft Substitutes (BGS) underperformed due to spine volume softness and competitive dynamics.
• Restorative Therapies (Exogen): Revenue of $21 million, down 3% YoY. Contributed approximately 15% of total revenue. Decline attributed to sales force vacancies, which have since been filled.
• International: Revenue of $18 million, up 16% YoY (18% constant currency). Contributed approximately 13% of total revenue. Growth driven by ultrasonics and HA businesses.

• Full-Year Revenue: Lowered to $590 million–$595 million (previously ~$607 million midpoint), reflecting mid-single-digit Q4 growth expectations and BGS headwinds.
• Full-Year Adjusted EPS: Reaffirmed at $0.75–$0.79 per diluted share.
• Full-Year Cash Flow: Reaffirmed cash from operations guidance of $84 million–$89 million.
• Segment Outlook: BGS expected to remain lower than prior expectations but show sequential acceleration in Q4. Restorative therapies expected to improve sequentially as sales force vacancies are filled. Pain treatments expected to see slightly lower growth rates in Q4 compared to a strong prior year base, but still positive.

• Bone Graft Substitutes (BGS) Headwinds: Near-term softness in spine procedures, temporary delays in adding new distributors, and competitive dynamics in the synthetic market impacted Q3 results.
• Sales Force Execution: Restorative therapies (Exogen) suffered volume impacts due to higher-than-normal vacancies in the sales force, though positions are now filled.
• Strategic Uncertainty: Ongoing strategic review creates uncertainty regarding future corporate direction, though management emphasizes long-term value creation.
• Competitive Dynamics: Specific competitive pressures in the synthetic BGS market required late-Q3 actions, though early signs of improvement are visible in October.

Q: Caitlyn Roberts asked for more detail on BGS headwinds and whether spine market softness would negatively impact ultrasonics adoption.

A: Rob Claypoole explained that BGS weakness was driven by two transitory factors: competitive dynamics in the synthetic space (addressed late Q3 with positive October results) and slower spine procedural volumes/distributor ramp-up. He noted that ultrasonics is largely unaffected because it is changing the standard of care in a large market, and its strong volume has overcome any procedural slowdowns. He reaffirmed confidence in the IDN strategy.

Q: Larry Solow requested granularity on the revised revenue guidance reduction, asking if the $12.5 million midpoint cut was solely due to BGS or if other segments like PRP/PNS missed targets.

A: Rob Claypoole clarified that more than half of the reduction occurred in Q3, primarily driven by BGS. The remainder of the cut for Q4 is due to BGS timing and the contribution lag from newly onboarded reps. He emphasized that sequential acceleration is expected in Q4 with mid-single-digit growth, noting positive traction already seen in the first month.

Q: Chase Knickerbocker asked if BGS weakness was isolated to Signifuse or how OsteoAmp performed, and inquired about customer behavior regarding biologics RFPs.

A: Rob Claypoole stated the impact was primarily in the synthetic space due to competition, while procedural slowdowns affected the broader portfolio. He highlighted positive October trends after late-September actions. Mark Singleton added that restorative therapies and pain segments expect sequential improvements. Rob Claypoole noted that large IDNs are separating biologics RFPs but basing decisions on clinical/economic value, where BioVentus is gaining traction.

Q: Mike Petusky asked about the status of the $13 million incremental investment target and whether ultrasonics growth is driven by deeper utilization or new user expansion.

A: Rob Claypoole revealed that investments accelerated to nearly $15 million, with over half going to P&S due to its opportunity size. He expressed confidence in the learnings and positive traction. Regarding ultrasonics, he confirmed the growth is driven by both expanding the user footprint (ahead of schedule) and increasing utilization/disposables among existing users, fueling double-digit growth.

Q: Larry Solow followed up on cost discipline, asking how SG&A remained flat despite increased investments and lower BGS revenue.

A: Mark Singleton explained that BGS has the lowest variable margins, so missing revenue there has a less material profit impact than missing in high-margin businesses. He attributed the ability to maintain margins and fund increased growth investments to the powerful underlying P&L structure, disciplined cost management, and the flexibility to adjust variable spending levers.